ALPHAGAN® 5 mL
Navigation Links
ALPHAGAN® 5 mL
| Products | ALPHAGAN® 5 mL |
| Company | Allergan, Inc. |
| Item | ALPHAGAN® 5 mL |
| Features | |
| Description | ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension. |
| Info | Allergan, Inc. Customer Service: (714) 246-4500 |
Related medicine products :
1. ALPHAGAN® P 5 mL
2. ALPHAGAN® P 10 mL
3. ALPHAGAN® P 15 mL
4. ALPHAGAN® 10 mL
5. ALPHAGAN® 15 mL
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance Praises Growing National Coalition 2Health News:Lung Cancer Alliance Praises Growing National Coalition 3Health News:Beckman Coulter to Host Annual Business Review 2Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 2Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 3Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 4Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 2Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 3Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 4Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 5Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 6Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 7Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 2Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 3
[0] Lung Cancer Alliance Praises Growing National Coalition[0] Beckman Coulter to Host Annual Business Review[0] AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding[0] New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe[0] Researchers identify barriers to HPV vaccination uptake in low-income populations
Other Medicine News:Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Many Turn Blind Eye to Racism 2Health News:Dance With Courage to Benefit Camp Courage 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2
SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers DelayedBipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol HillMany Turn Blind Eye to RacismDance With Courage to Benefit Camp CourageIPC The Hospitalist Company Acquires Missouri Practice GroupVeteran Environmental Health Expert Erik D. Olson to Join Pew
Breaking Medicine Technology:Giant Eagle(R) Pharmacy Receives Award for Operational Excellence 2Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 2Reportlinker Adds Medical Fiber Optics - A World Market Analysis 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 4Reportlinker Adds Medical Fiber Optics - A World Market Analysis 5Reportlinker Adds Medical Fiber Optics - A World Market Analysis 6United States Patent and Trademark Office Accepts CoolTouch 26apos 3Bs Re examination Request for Cynosure 26apos 3B873 Patent 47571 1United States Patent and Trademark Office Accepts CoolTouch 26apos 3Bs Re examination Request for Cynosure 26apos 3B873 Patent 47571 2Schering Plough Announces European Filing of SYCREST 28R 29 28asenapine 29 for the Treatment of Schizophrenia and Bipolar I Disorder 47568 1Schering Plough Announces European Filing of SYCREST 28R 29 28asenapine 29 for the Treatment of Schizophrenia and Bipolar I Disorder 47568 2University HealthSystem Consortium Adds Price Competitive Index to Its Spend Analytics Tool 47567 1University HealthSystem Consortium Adds Price Competitive Index to Its Spend Analytics Tool 47567 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |